


**Product Name** : Pirtobrutinib  
**Cat. No.** : PC-72630  
**CAS No.** : 2101700-15-4  
**Molecular Formula** : C<sub>22</sub>H<sub>21</sub>F<sub>4</sub>N<sub>5</sub>O<sub>3</sub>  
**Molecular Weight** : 479.436  
**Target** : BTK  
**Solubility** : 10 mM in DMSO



### Biological Activity

Pirtobrutinib (LOXO-305, LY3527727, RXC-005) is a highly potent and selective non-covalent **BTK** inhibitor with IC<sub>50</sub> of 5.69 nM.

LOXO-305 shows nanomolar potency against both wild-type and C481-mutated BTK.

LOXO-305 displays >300 fold selectivity on BTK over 98% of other kinases, reducing the potential for off-target toxicities.

Pirtobrutinib (LOXO-305) has been designed to maintain greater than 90% of maximal BTK inhibition at trough, thereby achieving effective target inhibition throughout the dosing interval, even in proliferative tumours.

### References

Brandhuber B, et al. Clin. *Lymphoma Myeloma Leuk.* 2018;18:S216.

Ito K, et al. *Eur J Cancer.* 2021 Mar;145:183-193.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com